Market Value to Book Value Ratio: Marinus Pharma (MRNS)
Marinus Pharmaceuticals (MRNS) relies on an academic culture and an ethical approach to epilepsy therapy. The company's current P/BV multiple illustrates a transition from monopoly pricing on orphan drugs to an acute crisis following failed tests of new medications. A struggle for survival now drives the dynamics, and the -0.46 metric serves as the target level for assessing the recovery of market confidence.
Marinus Pharmaceuticals Inc (MRNS) - metric breakdowns and financial figures
- market value and analyst target forecast:
- company stock exchange capitalization indicators:
- book capitalization data:
- debt and solvency information:
Debt to Equity Marinus Pharmaceuticals|MRNS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Marinus|MRNS - Company Cumulative Debt|Debt to Book Capitalization Ratio Marinus|MRNS - Company Long-Term Liabilities|Company Short-Term Debts Marinus Pharmaceuticals|Quick Liquidity marinuspharma.com
- earnings and valuation multiples indicators:
Comprehensive company analysis:Marinus Pharmaceuticals
This indicator compares the market value of the business with its net assets to determine the size of the market premium. The formula measures the gap between the book valuation and real-time market expectations. By analyzing the trend of the market-to-book ratio, an investor can identify the risk of a "value trap." For Marinus Pharmaceuticals (MRNS), this is critical when optimizing staff and rotating R&D. The current valuation reflects the market's confidence in the commercial success of Ztalmy despite personnel reshuffles.
Main competitors
Biogen Inc. (BIIB) - Market Value to Book Value Ratio|NBIX - Market Capitalization to Book Value|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited|Capitalization to Book Value Ratio AXSM (Axsome)|Market Capitalization to Book Value Ratio ACAD|XENE - Market-to-Book Ratio|Viking Therapeutics - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio supernus.com SUPN|CPRX - Market Value to Book Value Ratio|Market Value to Book Value DNLI (Denali)|Harmony Pharma (HRMY) - Market Value to Book Value Ratio|Market-to-Book Ratio Biohaven Corp (BHVN)|Market Value to Book Value Ratio Amylyx Pharmaceuticals|Market Cap to Net Assets Ratio trevitherapeutics.com (TRVI)|Market Capitalization to Book Value Ratio PRAX|Market Capitalization to Book Value Ratio Anavex (AVXL)|Market Value to Book Value Ratio CeriBell Corp CBLL|Market Value to Book Value PRTA|Alector Therapeutics - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value annexonbio.com ANNX|omeros.com (OMER) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio NGNE|Market Cap to Net Assets Ratio ACIU|Market Capitalization to Book Value Ratio Voyager Corp|Market Value to Book Value Ratio Neumora Therapeutics (NMRA)|Market Capitalization to Book Value scilexholding.com|Tevogen Bio - Market Cap to Net Assets Ratio|Market Value to Book Value ACOG|CGTX - Market Value to Book Value Ratio|Market Capitalization to Net Assets IKT|SAVA: Market Capitalization to Book Value Ratio|Assertio - Market Value to Book Value|COYA (Coya Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio VistaGen Therapeutics Inc|Market Value to Book Value Ratio Ovid Therapeutics Inc. (OVID)|ABOS (Acumen Pharmaceuticals, Inc) - Market Value to Book Value|Market Value to Book Value Ratio CervoMed Inc. CRVO|ATHE - Market Cap to Net Assets Ratio|Clene Nanomedicine - Market Capitalization to Book Value Ratio|PEPG - Market Capitalization to Book Value Ratio|JUNS: Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Relmada Corp|ANVS (Annovis Bio, Inc.) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Grace Tx GRCE|Market Cap to Net Assets Ratio AIFF (Firefly Neuroscience)|Market Capitalization to Book Value Ratio anewmeds.com (KLTO)|NeuroSense Therapeutics Ltd. - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple RVPH (Reviva Pharmaceuticals, Inc.)|MetaVia, Inc. - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value neuraxis.com NRXS|HSDT: Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Passage Bio|NEUP (Neuphoria Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Minerva|Market Value to Book Value Ratio Athira Pharma, Inc. (ATHA)|Market Value to Book Value Ratio ADXN (addextherapeutics.com)|Market Value to Book Value Ratio Alzamend Neuro ALZN|Market Capitalization to Book Value Cyclerion Therapeutics Inc. (CYCN)|PTIX - Market Value to Book Value Ratio|Pasithea Therapeutics (KTTA) - Market Cap to Net Assets Ratio|cortigent.com (CRGT) - Market Value to Book Value Ratio|avenuetx.com - Market Value to Book Value|Market Value to Book Value Ratio BrainStorm Cell Therapeutics|Capitalization to Book Value Ratio CARA (Cara Therapeutics Inc.)|Market Value to Book Value Ratio Chromocell Therapeutics Corporation (CHRO)|Market Capitalization to Book Value eliemtx.com|Market Value to Book Value Ratio Intra-Cellular Therapies, Inc. ITCI|LBPH: Capitalization to Book Value Ratio|NKGen Biotech - Market Capitalization to Book Value Ratio|Market-to-Book Ratio NeuroBo Pharmaceuticals Inc|SAGE (Sage Therapeutics, Inc) - Market Cap to Net Assets Ratio|Synaptogenix, Inc (SNPX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Trevena, Inc.|VIGL: Market Value to Book Value|Market Value to Book Value Ratio Anew Medical, Inc. (WENA)|CERE - Market-to-Book Ratio